2024
The NAVigate-HPV Registry: A comprehensive biomarker evidence base for HPV-driven cancers.
Roof S, Hanna G, Rettig E, Routman D, Holsinger F, Kalman N, Bhatia A, Patel M, Jabalee J, Yom S, Baliga S, Raben A, Sims J, Kaczmar J, Bhayani M, Berger B, Del Vecchio Fitz C. The NAVigate-HPV Registry: A comprehensive biomarker evidence base for HPV-driven cancers. Journal Of Clinical Oncology 2024, 42: e15045-e15045. DOI: 10.1200/jco.2024.42.16_suppl.e15045.Peer-Reviewed Original ResearchHPV-driven cancersHPV-related cancersHuman papillomavirusClinical dataHead and neckClinical outcome dataBlood-based assayPrecision cancer medicineClinical careRoutine clinical careDNA scoreUterine cervixAcademic medical facilityImprove patient outcomesAnal canalClinicopathological featuresEligible subjectsU.S. cancer centersBlood testsOncogenic driversCancer CenterTherapeutic approachesTumor biomarkersPatientsCancer medicine
2021
Innovative Chemotherapy‐free Approaches for the Treatment of Peripheral T‐Cell Lymphoma
Marchi E, Sawas A, Ma H, Scotto L, Montanari F. Innovative Chemotherapy‐free Approaches for the Treatment of Peripheral T‐Cell Lymphoma. 2021, 367-377. DOI: 10.1002/9781119671336.ch27.Peer-Reviewed Original ResearchPrimary cutaneous T-cell lymphomaT-cell lymphomaHypomethylating agentPeripheral T-cell lymphomaCutaneous T-cell lymphomaChemotherapy-free approachConventional cytotoxic chemotherapyCare of patientsDrug-drug combinationsNew therapeutic agentsCytotoxic chemotherapyPreclinical observationsTherapeutic agentsKinase inhibitorsPhase ICancer medicineProteasome inhibitorsLines of evidenceLymphomaSubsequent developmentInhibitorsDrugsAgentsChemotherapyPatients
2020
Abstract 37: Computational analysis of the KRAS G13D colorectal cancer response to EGFR inhibition with an alternatively parameterized model
McFall T, Stites E. Abstract 37: Computational analysis of the KRAS G13D colorectal cancer response to EGFR inhibition with an alternatively parameterized model. Clinical Cancer Research 2020, 26: 37-37. DOI: 10.1158/1557-3265.advprecmed20-37.Peer-Reviewed Original ResearchColon cancer cellsMultiple colon cancer cell linesBiochemical rate constantsCancer cellsColon cancer cell linesCell linesResponse to EGFR inhibitionKRAS mutantRAS biologyCancer cell linesRas signalingEGFR inhibitionMedicinal drug developmentSignaling regulationComputational analysisPersonalized cancer medicineMutantsG13D mutantWild-typeCombination of computational modelingEGFR inhibitor cetuximabColorectal cancer patientsDrug developmentCellsCancer medicine
2016
Scientific Advances in Lung Cancer 2015
Tsao AS, Scagliotti GV, Bunn PA, Carbone DP, Warren GW, Bai C, de Koning HJ, Yousaf-Khan AU, McWilliams A, Tsao MS, Adusumilli PS, Rami-Porta R, Asamura H, Van Schil PE, Darling GE, Ramalingam SS, Gomez DR, Rosenzweig KE, Zimmermann S, Peters S, Ou S, Reungwetwattana T, Jänne PA, Mok TS, Wakelee HA, Pirker R, Mazières J, Brahmer JR, Zhou Y, Herbst RS, Papadimitrakopoulou VA, Redman MW, Wynes MW, Gandara DR, Kelly RJ, Hirsch FR, Pass HI. Scientific Advances in Lung Cancer 2015. Journal Of Thoracic Oncology 2016, 11: 613-638. PMID: 27013409, DOI: 10.1016/j.jtho.2016.03.012.Peer-Reviewed Original ResearchConceptsLung cancerMajor global health problemSpecific oncogenic driversLung cancer therapyGlobal health problemLung cancer researchOncogene-driven tumorsQuality of lifeImportant therapeutic breakthroughsAdvanced diseaseImmunotherapy fieldPrecision cancer medicineNew patientsNew agentsTherapeutic breakthroughHealth problemsOncogenic driversCancerTherapyCancer medicinePast yearSignificant scientific advancementsCancer 2015Cancer therapyRegulatory approval
2015
Tumor profiling and the incidentalome: patient decisions and risks
Hofstatter E, Mehra K, Yushak M, Pusztai L. Tumor profiling and the incidentalome: patient decisions and risks. Future Oncology 2015, 11: 3299-3305. PMID: 26562094, DOI: 10.2217/fon.15.260.BooksConceptsTumor profilingField of oncologyTumor DNA sequencesOncology patientsIncidental discoveryPatient educationPatient's perspectivePatient decisionOncology communityClinical implicationsPatient healthGermline mutationsCancer medicineGenetic sequencingCancer therapyTherapyPotential riskRiskHealthPatientsIncidentalomeMainstayDiseaseOncologyProfiling
2013
Chemical kinetic mechanistic models to investigate cancer biology and impact cancer medicine
Stites E. Chemical kinetic mechanistic models to investigate cancer biology and impact cancer medicine. Physical Biology 2013, 10: 026004. PMID: 23406820, DOI: 10.1088/1478-3975/10/2/026004.Peer-Reviewed Original ResearchConceptsBiochemical networksCancer biologyInvestigate cancer biologyDisrupt cellular processesAcquisition of mutationsCellular processesClinical management of cancer patientsMutated genesCancer medicineMolecular biologyExperimental biologyFeatures of cancerBiologyMutationsMechanistic modelExperimental approachGenesMolecular reactionsPace of progressKinetic mechanistic modelsCancerManagement of cancer patients
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply